Skip to Content

Roflumilast use while Breastfeeding

Drugs containing Roflumilast: Daliresp

Medically reviewed by Drugs.com. Last updated on Feb 1, 2021.

Roflumilast Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the use of roflumilast in nursing mothers. The drug and its metabolite are more than 97% bound to plasma proteins, so amounts in milk are likely to be very low. However, the manufacturer states that the drug should not be used by women who are nursing.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Roflumilast

CAS Registry Number

162401-32-3

Drug Class

Breast Feeding

Lactation

Phosphodiesterase 4 Inhibitors

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.